Fulcrum Therapeutics, INC. (FULC) — 10-Q Filings

10-Q Filings (6)

• Fulcrum's Losses Mount to $54.5M Amidst Zero Collaboration Revenue — Oct 29, 2025 Risk: high
  Fulcrum Therapeutics, Inc. reported a significant net loss of $54.5 million for the nine months ended September 30, 2025, a substantial increase from a net inco
• Fulcrum's Q2 Loss Widens Amid Soaring R&D Costs — Jul 29, 2025 Risk: high
  Fulcrum Therapeutics, Inc. reported a net loss of $48.2 million for the three months ended June 30, 2025, a significant increase from the $34.5 million net loss
• Fulcrum Therapeutics Files Q1 2025 10-Q — May 1, 2025 Risk: medium
  Fulcrum Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company's fiscal year ends on December 31st. Key financial data points and d
• Fulcrum Therapeutics Files Q3 2024 10-Q — Nov 13, 2024 Risk: medium
  Fulcrum Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial position and operational activities. K
• Fulcrum Therapeutics Files Q2 2024 10-Q — Jul 31, 2024 Risk: medium
  Fulcrum Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business o
• Fulcrum Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 13, 2024 Risk: medium
  Fulcrum Therapeutics, Inc. (FULC) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Fulcrum Therapeutics, Inc. filed a 10-Q report for the period en

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX